Work

A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

Year: 2021

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-021-04350-x

Authors: Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice Chen, Jan H. Beumer, Janice M. Mehnert

Institutions: Rutgers, The State University of New Jersey, Levine Cancer Institute, Rutgers Cancer Institute, University of Pittsburgh, Columbia University Irving Medical Center, Bristol-Myers Squibb (United States), Frederick National Laboratory for Cancer Research, National Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis, G3527843217, Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01), Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, NCI ETCTN Pittsburgh Cancer Consortium (PCC), Dr. Salma Jabbour’s NCI Research Specialist (Clinician Scientist) Award (R50), PITT-CAL ETCTN PK Resource Laboratory, Cancer Center Support Grant, Cancer Pharmacokinetics Research Specialist

OpenAlex ID: W3207103941

FWCI: 0.182

Cites: 22

Cited by: 5

Related to: 10